Apremilast Use in Oligoarticular Psoriatic Arthritis

We read with interest the article published in The Journal of Rheumatology by Ogdie et al 1 in which apremilast monotherapy showed more benefit in a specific subset of the psoriatic arthritis (PsA) population (oligoarticular pattern), compared to methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs). The authors collected baseline and follow-up data (6-month period) regarding the clinical response to either MTX, apremilast, or bDMARD, all in monotherapy.